Systemic Sclerosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for systemic sclerosis. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
1
Active US patents
50/100
Avg vulnerability
—
Annual revenue covered

Originators in Systemic Sclerosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating systemic sclerosis. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
27

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tracleer
BOSENTAN
 AstraZeneca 1 50 — 2027-12-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7959945 Tracleer formulation 55 2027-12-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7959945 Tracleer formulation 55 2027-12-28

Related